Neuro-Oncology Practice · 2019 · 27 citations · 38 references
MedicineNeuroscienceOncologyBreast OncologyMetastasisNeuro-oncologyBrain MetastasesBrain MetastasisMetastatic Brain TumorsMetastatic Breast CancerMetastatic Disease TreatmentNeuro-oncology Clinical TrialsBrain Metastasis TrialsPhase Ii Clinical TrialsPhase Ii Oncology TrialsPhase Iii Clinical TrialsPhase Iii Oncology TrialsRandomized Clinical TrialsSample Size CalculationTherapeutic Trials
BACKGROUND: Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology for which more efficacious therapies are required. In this work, we explore clinical trials in BCBM, and determine the shortcomings in the development of new BCBM therapies to shed light on potential areas for enhancement. METHODS: On July 9, 2018, we searched ClinicalTrials.gov for all interventional and therapeutic clinical trials involving BCBM, without limiting for date or location. Information on trial characteristics, including phase, status, start and end dates, study design, primary endpoints, selection criteria, sample size, experimental interventions, results, and publications were collected and analyzed. RESULTS: Fifty-three trials fulfilled the selection criteria. Median trial duration across phases ranged between 3 and 6 years. More than half of the trials were conducted in the United States. Although 94% of the trials were in early phases (I-II), 20% of patients were in phase III trials. Two phase III trials were anteceded by phase II trials that were non-randomized; one reported positive results. Approximately one-third of the trials were completed, whereas 23% of trials were terminated early; mostly due to inadequate enrollment. Only 13% of all trials and 22% of completed trials had published results directly linked to their primary outcomes. CONCLUSIONS: The low number of trials and accrual numbers, the lack of diversity, and the scarcity of published results represent the main troubles in clinical BCBM research. Optimization of BCBM trials is necessary to achieve effective therapies.
38
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Genes that mediate breast cancer metastasis to the brain
Paula D. Bos, Xiang H.-F. Zhang, Cristina Nadal et al. · Nature · 2009 · 1.9K citations · Full text
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text